Experimental treatment selectively reduces harmful protein in lab models of rare inherited brain disorder
Researchers from DZNE and the Hertie Institute for Clinical Brain Research (HIH) at the University of Tübingen, together with experts from Bonn, London and Portugal, have developed and successfully tested in human neurons cultured in the lab a new approach for treating the rare neurodegenerative disease spinocerebellar ataxia type 3 (SCA3).
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Transplanted placental cells successfully detected in mouse pancreas after birth
United Kingdom
-
Study reveals how melanoma outmaneuvers both drugs and immune defenses
United Kingdom
-
Cardiac MRI reveals distinct mechanisms in heart failure with preserved ejection fraction
United Kingdom
-
Short gaps between pregnancies may accelerate biological aging in mothers
United Kingdom
-
Gaining too much weight during pregnancy raises complication risks
United Kingdom
-
Starting survivorship care earlier improves head and neck cancer survival
United Kingdom
-
New AI platform helps uncover promising cancer drug combinations
United Kingdom
-
Gut bacteria use food signals to manage body's biological clock
United Kingdom